Ken Griffin’s Autolus Therapeutics AUTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$174K Buy
126,400
+71,500
+130% +$109K ﹤0.01% 11551
2025
Q4
$109K Buy
54,900
+42,900
+358% +$65.9K ﹤0.01% 11562
2025
Q3
$19.6K Buy
+12,000
New +$23.4K ﹤0.01% 12493
2024
Q4
Sell
-2,800
Closed -$10.2K 14470
2024
Q3
$10.2K Sell
2,800
-8,900
-76% -$35.5K ﹤0.01% 13220
2024
Q2
$40.7K Sell
11,700
-65,700
-85% -$284K ﹤0.01% 11970
2024
Q1
$494K Buy
77,400
+61,400
+384% +$383K ﹤0.01% 8430
2023
Q4
$103K Buy
+16,000
New +$61K ﹤0.01% 10896
2023
Q3
Sell
-18,100
Closed -$43.1K 14258
2023
Q2
$43.1K Sell
18,100
-9,100
-33% -$21.6K ﹤0.01% 11982
2023
Q1
$50K Sell
27,200
-5,300
-16% -$10.4K ﹤0.01% 12139
2022
Q4
$61.8K Buy
+32,500
New +$82.2K ﹤0.01% 11880
2022
Q3
Sell
-18,600
Closed -$53K 12576
2022
Q2
$53K Buy
+18,600
New +$56.6K ﹤0.01% 11895
2022
Q1
Sell
-36,900
Closed -$192K 13547
2021
Q4
$192K Sell
36,900
-47,700
-56% -$286K ﹤0.01% 11899
2021
Q3
$554K Buy
+84,600
New +$534K ﹤0.01% 9614

Other funds holding AUTL

Ken Griffin's AUTL Position: Q1 2026 in Review

Ken Griffin reduced its Autolus Therapeutics (AUTL) stake by 60% in Q1 2026, selling an estimated $1.06M and leaving 459,404 shares worth $634K. The position accounts for ﹤0.01% of the portfolio, ranked #8717.

Ken Griffin first reported a position in AUTL in Q2 2019 and has held it in 26 quarters since. The position peaked at $18.3M in Q2 2021. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

  • Ken Griffin held 459,404 shares of Autolus Therapeutics worth $634K as of Q1 2026.
  • Ken Griffin sold 700,387 Autolus Therapeutics shares in Q1 2026, an estimated $1.06M.
  • Autolus Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #8717 holding.
  • Ken Griffin first reported a position in Autolus Therapeutics in Q2 2019 and has held it in 26 quarters since.
  • Ken Griffin's Autolus Therapeutics position peaked at $18.3M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.